Annie Kennedy's Blog – February 2016 Archive (1)
Advancing Targeted Therapies for Rare Diseases Act Goes Before HELP Committee
For nearly two years, PPMD has been working with Congressional champions and industry partners to help lead an effort to streamline the regulatory pathways and review processes for targeted therapeutics (which would include such things as ‘follow on exons’) by clarifying the FDA’s existing authority to leverage data previously used in the approval of a targeted product when approving a new therapy. These efforts have yielded a provision in the House of Representatives…
ContinueAdded by Annie Kennedy on February 9, 2016 at 3:36pm — 8 Comments
Latest Blog Posts
- Action Alert! Americans with Disabilities Act (ADA) in Jeopardy
- Action Alert! Americans with Disabilities Act (ADA) in Jeopardy
- Meet the 2018 PPMD Adult Advisory Committee (PAAC)
- 2018 Off to a Strong Start — 'Patient Experience Data’ Section Added to FDA Reviews
- Take Action - We Can Still Impact the Tax Reform Bill
- PPMD Signs Letter to Congressional Leaders re: National Defense Authorization Act (NDAA) Language
- Updates in Duchenne Newborn Screening Efforts
Most Popular Blog Posts
- ACTION ALERT: Tell Your Senator to Vote NO on Today's Healthcare Repeal!
- The Big Day is Almost Here!
- PPMD Response to the House Passage of the American Health Care Act
- BREAKING NEWS: 21st Century Cures Crossed Over the Finish Line!
- Action Alert: If Passed, Proposed Tax Plans from Both Houses Will Affect Duchenne Community
- FDA Pediatric Advisory Committee Unanimously Votes YES — Now Moves to Commissioner
- 21st Century Cures Passes House of Representatives!
© 2021 Created by PPMD.
Powered by
Badges | Report an Issue | Privacy Policy | Terms of Service
